skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia

Review

(2006) Views  (631) Full article downloads

Authors: Jun Sasaki

Published Date November 2010 Volume 2010:6 Pages 997 - 1005
DOI: http://dx.doi.org/10.2147/VHRM.S7802

Jun Sasaki
Pharmaceutical Medicine, International University of Health and Welfare Graduate School, Fukuoka, Japan

Abstract: Pitavastatin was first developed in Japan and is expanding the regions in which it is clinically available. A considerable number of clinical studies have been conducted and published to date on the usefulness of pitavastatin for patients with primary hypercholesterolemia or combined dyslipidemia. Pitavastatin demonstrates potent low-density lipoprotein cholesterol reduction at low doses of 1–4 mg/day. It also affects the regression of coronary plaques, as observed in intravascular ultrasound-guided percutaneous coronary intervention studies. Moreover, the persistent, long-term high-density lipoprotein cholesterol elevation observed in the populations treated with pitavastatin is worthy of further attention. The reported improvements in lipid profiles are consistent among the studies conducted in Japan, Korea, Thailand, and Europe. In light of accumulating clinical experience worldwide, pitavastatin is now expected to establish its position for preventing and treating cardiovascular disease.

Keywords: randomized clinical trial, Japan, Korea, Thailand, Europe






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
Management of acute attacks of hereditary angioedema: potential role of icatibant
Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University